Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob Swift who wrote (1877)	3/2/1999 8:40:00 PM
From: Biomaven	Read Replies (1) of 10280

Bob, Xopenex has the same short-term side effects as half the equivalent dose of albuterol. This isn't necessarily the same as reducing the side-effects by 50%, but it's probably in the same ball-park. The oxybutynin example is a particularly hard one to interpret, because you likely have a different mode of action. Clearly side-effects were substantially lessened; if they didn't significantly lower efficacy as well (as they seem to claim), the new drug should do very well. This is a very hard area in which to demonstrate anything conclusively because of the big placebo effect. We'll need more and bigger trials to nail down the precise advantages. Remember that for some of the drugs like Hismanal and Cisapride the old drug is simply going to disappear (like Seldane), and there will be no generic competition to worry about. Claritin has had some reported drug interactions, but probably not enough to justify removing it from the market when Claritin II is released. Thus Claritin II and Prozac II are partly going to be tests of how big marketing muscle and some underlying improvement are going to stack up against the generic. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next